Our IPA results predict that FXYD5 expression may be upregulated through the activation of major oncogenes (e.g., CTNNB1, MET, and TERT) and the loss of tumor suppressors (e.g., TP53 and AXIN1), suggesting that dysadherin upregulation could represent a convergent outcome of primary driver mutations in HCC (Supplementary Fig. 7i). The gene discussed is FXYD5; the disease is hepatocellular carcinoma.